Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
US11718619B2 · kind B2 · utility
0Cited by
3References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 7, 2021 |
| Grant date | Aug 8, 2023 |
| Priority date | — |
| Expiry date | Aug 1, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P3/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, L2, A, B, R1, R2, R3, and R4 are described herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.